Back to home » Treatment News
 May 30, 2008
|
Calming the Immune System to Treat HIV
The greater the calming effect of antiretroviral (ARV) therapy on the immune system during the first few weeks of treatment, the better the chance of maintaining an undetectable viral load over time, according to a new study published in the June 1 issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
May 29, 2008
|
Norvir-Boosted Protease Regimen Bests Other Regimens
People taking an antiretroviral (ARV) treatment regimen that includes a protease inhibitor (PI) boosted with low-dose Norvir (ritonavir) were less likely to develop drug resistance than people taking other types of regimens, according to the authors of a study published in the July 1 issue of the Journal of Infectious Diseases.
|
|
|
May 28, 2008
|
Monitoring Board Finds HIV Combo Inferior
A monitoring board for an international trial comparing three antiretroviral (ARV) regimens has found that Reyataz (atazanavir) combined with Emtriva (emtricitabine) and Videx-EC (didanosine) is inferior to the others studied in terms of viral control.
|
|
|
May 27, 2008
|
Gold Nanoparticles Revive HIV Drug’s Prospects
Adding minuscule bits of gold, called nanoparticles, to a failed HIV drug causes it to work much better without creating dangerous side effects, say the authors of a study published online on May 13 in the Journal of the American Chemical Society and reported by ScienceDaily.
|
|
|
May 23, 2008
|
Good Results in Long-Term HCV Treatment Follow-Up
The majority of people effectively treated with hepatitis C virus (HCV) therapy remain free of the virus five years later, say the authors of a study presented last week at the 2008 Digestive Disease Week Conference in San Diego.
|
|
|
Latinos Respond Less Well to HCV Treatment
HIV-negative Latinos are less likely to respond to hepatitis C virus (HCV) treatment than HIV-negative white non-Latino patients, according to a study presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) in Milan, and reported May 19 by the National AIDS Treatment Advocacy Project (NATAP).
|
|
|
May 22, 2008
|
Thalidomide Helps HIV-Related Colitis
Three HIV-positive patients with ulcerative colitis had complete resolution of the disease after treatment with thalidomide, according to an article to be published in a forthcoming issue of Clinical Infectious Diseases.
|
|
|
May 21, 2008
|
Lingering Side Effects Reported With Facial Filler
People who have injections of the facial filler polyalkylimide may have immune-related side effects many months after the injections, say the authors of a study published in the May 2008 issue of the Archives of Dermatology.
|
|
|
Anal and Other Cancer Rates Higher in HIV
People living with HIV are being diagnosed with many types of cancers at rates that are much higher than in the general population, say the authors of a study to be published in a forthcoming issue of the Annals of Internal Medicine.
|
|
|
May 20, 2008
|
New HIV Drug Discovery
In their discovery of a new way to inhibit formation of HIV’s protease enzyme, scientists may have identified a new drug target, according to new data published in the August 2008 issue of Biopolymers and reported today by ScienceDaily.
|
|
|
May 19, 2008
|
GSK Responds to Accusations About Abacavir
GlaxoSmithKline (GSK) asserts it has been fully forthcoming regarding its drug abacavir (found in Ziagen, Epzicom and Trizivir) and a possible link to heart attacks, according to a letter GSK sent late last week to The Independent.
|
|
|
Viracept OK Again for Children, Pregnant Women
Pfizer has met new manufacturing standards set by the Food and Drug Administration (FDA) for Viracept (nelfinavir), and the drug is now considered safe again for use in children and pregnant women in the United States, according to a letter sent to health care providers by Pfizer earlier this month.
|
|
|
May 15, 2008
|
New Developments in Abbott’s Norvir Court Case
Documents involved in a class-action lawsuit against Abbott Laboratories, over a 400 percent price increase of its protease inhibitor (PI) Norvir (ritonavir) in 2003, have been unsealed, according to an announcement by Prescription Access Litigation (PAL), a coalition of 130 health-advocacy groups.
|
|
|
May 14, 2008
|
Immune Cells Harbor Infectious Virus
Scientists have confirmed that a cell responsible for early immune responses to infections also offers a way for HIV to escape from the effects of antiretroviral (ARV) treatment, according to a study appearing in the June issue of the Journal of Virology and reported by Medical News Today.
|
|
|
May 13, 2008
|
High Cholesterol Good for Hepatitis C Treatment?
Having higher levels of “bad” low-density lipoprotein (LDL) cholesterol is associated with a better response to hepatitis C (HCV) treatment in people infected with both HIV and HCV, say the authors of a study published in the May 11 issue of AIDS.
|
|
|
May 12, 2008
|
Spying on an HIV Enzyme
Through sophisticated molecular sleuthing a group of scientists from Harvard and the National Cancer Institute (NCI) has shown for the first time just how nimble the HIV enzyme reverse transcriptase (RT) really is, according to a report by ScienceDaily.
|
|
|
Can Antidepressants Also Boost the Immune System?
The antidepressant Celexa (citalopram) increases the activity of natural killer (NK) cells—a critical line of defense against cancer and infectious diseases like HIV—say the authors of a new study published in the May 1 issue of Biological Psychiatry and reported by ScienceDaily.
|
|
|
GSK Hasn’t Mentioned Heart Attacks Reported in 2005 Letter
GlaxoSmithKline (GSK) neglected to mention a 2005 report involving 34 heart attacks among HIV-positive people taking abacavir (found in Ziagen, Epzicom and Trizivir) in its response to the results of a recent study finding a 90 percent increased risk of a heart attack associated with the use of the drug, according to an article today in The Independent.
|
|
|
May 09, 2008
|
Bone Marrow Deficits May Explain Blunted CD4 Response
The suppression and dysfunction of stem cells in bone marrow may help explain why some people don’t experience significant CD4 cell increases after starting antiretroviral (ARV) therapy, say the authors of a study to be published in a future issue of Clinical Infectious Diseases.
|
|
|
May 08, 2008
|
Higher-Dose Kaletra Plus Rifampicin Creates Liver Toxicity
Taking Kaletra (lopinavir/ritonavir) at doses higher than generally recommended in conjunction with the tuberculosis (TB) medication rifampicin causes serious side effects including vomiting and liver toxicity, say the authors of a study published in the May 11 issue of AIDS.
|
|
|
May 07, 2008
|
Majority of Patients Will Be Able to Use Intelence
Intelence (etravirine) is likely to work well in the vast majority of people who’ve had treatment failures from Sustiva (efavirenz) and Viramune (nevirapine), according to a research letter published in the May 11 issue of AIDS.
|
|
|
Antiretrovirals Vital in Treating Cancer
Antireteroviral (ARV) treatment and chemotherapy, more than any other factors, substantially increase the odds that a person with Kaposi’s sarcoma (KS)—a type of skin cancer common with HIV—will see their cancer improve and even go away, say the authors of a study published in the May 11 issue of AIDS.
|
|
|
May 06, 2008
|
Experimental HCV Treatment Shows Real Promise
Vertex Pharmaceutical’s experimental protease inhibitor for hepatitis C virus (HCV), telaprevir, was more effective when added to standard therapy than standard therapy alone, cuts treatment time from 12 to six months, and may help people who have failed approved treatments, according to several presentations reported by the National AIDS Treatment Advocacy Project (NATAP) from the recent 43rd annual meeting of the European Association for the Study of the Liver (EASL) in Milan.
|
|
|
New Report: Some ADAPs Cover HCV Treatment
While the majority of AIDS Drug Assistance Programs (ADAPs) are unable to provide pegylated interferon and ribavirin to HIV-positive people coinfected with hepatitis C virus (HCV), some do extend coverage to those in need of HCV treatment or therapies to manage side effects, according to a new guide produced by the Treatment Action Group (TAG).
|
|
|
May 05, 2008
|
Stimulated Cells Control SIV, and Hopefully HIV
A method for enhancing immune responses to simian immunodeficiency virus (SIV), the monkey version of HIV, was able to significantly control viral reproduction in infected macaques, say the authors of a study published in the online journal PLoS Pathogens.
|
|
|
May 02, 2008
|
“Video Doctor” Reduces Unsafe Sex and Drug Use
People living with HIV who received computerized video risk-reduction counseling before following up with a live doctor had less unprotected sex and used fewer illicit drugs than those who did not, according to the authors of a study published April 23 in the online journal PLoS One.
|
|
|
May 01, 2008
|
Rate of Heart Attacks Stable Despite Increased Risk
Though the number of people with HIV who have risk factors for heart disease and stroke is growing, effective management of those risk factors is keeping the number of heart attacks stable, say the authors of a study published in the April 1 issue of Clinical Infectious Diseases.
|
|
|
|
|
Have news about HIV? Send press releases, news tips and other announcements to news@poz.com. |
|
  November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
|
